

- 1) CUP C63C24000380006 - PNRR-MCNT2-2023-12377373, “Deconvoluting Epigenetics of Diabetes to Unmask Concealed Markers in T2D (DEDUCT)” € 767.600,00 (settecentosessatasettemilaseicento/00)
- 2) CUP C23C24000370001 - PNRR-MCNT2-2023-12378225, “LUNG ULTRASOUND (US) GUIDED TREATMENT OF HEART FAILURE IN PATIENTS WITH STAGE 3b-5 CKD PATIENTS (LUST2 TRIAL)” - €437.250,00 (Quattrocentotrentasettemiladuecentocinquanta/00)
- 3) CUP C63C24000360006 - PNRR-MCNT2-2023-12378490, “An integrated nanophotonics-multiomics platform for the stratification of breast cancer patients for diagnostic purposes” - €1.000.000,00 (un milione/00)
- 4) CUP C63C24000320006 - PNRR-MCNT2-2023-12378307, “Identification of new diagnostic and prognostic markers by comprehensive approach of genomic and imaging diagnosis in pediatric tumors” €860.000,00 (ottocentosessantamila/00)
- 5) CUP C63C24000370006 - PNRR-MCNT2-2023-12377713, “Imaging of pre-metastatic niche for an early theranostic intervention” €900.000,00 (novecentomila/00)
- 6) CUP I53C23002670006 - PNRR-MCNT2-2023-12378329, “Role of gender, genetic polymorphisms and drug-drug interactions in predicting adverse drug reactions in comorbid elderly patients with chronic heart failure on polypharmacy regimen.” €850.000,00 (ottocentocinquantamila/00)
- 7) CUP I53C23002700007 - PNRR-MCNT2-2023-12378283, “Advanced robotic beds for the early rehabilitation of cardiac surgery patients” - €983.000,00 (novecentottantatremila/00)
- 8) CUP 63C24000330006 - PNRR-MCNT2-2023-12377808, “Personalized medicine in cardiovascular diseases: a biomarker signature for high and very high patients” €1.000.000,00 (un milione/00)
- 9) CUP I53C23002680006 - PNRR-MCNT2-2023-12378074, “A multiomic approach for diagnosis and follow-up of eosinophilic esophagitis: from bench to bedside” €890.000,00 (ottocentonovantamila/00)
- 10) CUP I69I24000140001 - PNRR-MCNT2-2023-12377629, “Liquid biopsy, radiomic features and gut microbiota analysis for personalized treatment and continuity of care with immunotherapy plus targeted agents in metastatic colorectal cancer patients” - €1.000.000,00 (un milione/00)
- 11) CUP C63C23001430007 - PNRR-MCNT2-2023-12378040, “Measuring Immunological Self-Tolerance Reservoir to Validate Innovative Therapies in Patients with Relapsing-Remitting Multiple Sclerosis Acronym: ImmuneTolerance4Therapy” - €1.000.000,00 (un milione/00)
- 12) CUP H63C24000220006 - PNRR-MCNT2-2023-12377339, “Emerging electrocardiographic, echocardiographic, biomarkers and genetic predictors of life-threatening arrhythmias in adult and paediatric patients with non-ischemic cardiomyopathy” - €500.000,00 (cinquecentomila/00)
- 13) CUP I65E24000030005 - PNRR-MCNT2-2023-12378387, “MIND-Project: Multimodal Imaging, Neurobiological and Digital assessment for individualized sustainable detection, monitoring and management of parkinsonism in real-life setting” - €980.000,00 (novecentottantamila/00)

- 14) CUP I65E24000060006 - PNRR-POC-2023-12378248, “Rescuing eyes from nonsense: a precision medicine approach to rescue stop mutation in hereditary ocular diseases by translational readthrough inducing drugs - €950.000,00 (novecentocinquantamila/00)
- 15) CUP I63C24000220006 - PNRR-POC-2023-12378333 - Augmented-RObotic Gross Examination for solid tumoRs (ARoGER)” - €997.095,00 (novecentonovantasettemilanovantacinque/00)
- 16) CUP C63C24000400006 - PNRR-TR1- 2023-12378404, dal titolo “New therapeutics targets with clinical intervention for both paediatric and adult Brain cancer” – € 998.000,00 (novecentonovantottomila/00)